Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Clinical trial NCT00061633 · COMPLETED

Trial details

NCT number: NCT00061633
Sponsor: Cumberland Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Infections, Gram-Positive Bacterial Abscess Burns Cellulitis Ulcer Wound Infections

Start date: 2003-06-01
Primary completion: 2004-01-01
Enrollment: 169

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.